Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 0	$ 0
Operating expenses:
Research and development	19,487,000	18,968,000
General and administrative	10,017,000	11,542,000
Depreciation and amortization	127,000	130,000
Total operating expenses	29,631,000	30,640,000
Loss from operations	(29,631,000)	(30,640,000)
Other income:
(Loss) gain from change in fair value of warrant liability	(1,044,000)	1,335,000
Transaction costs allocated to warrant liabilities	(510,000)	0
Other income, net	48,000	40,000
Interest income, net	1,368,000	240,000
Net loss	$ (29,769,000)	$ (29,025,000)
Net loss per common share - basic and diluted (in dollars per share)	$ (15.07)	$ (15.22)
Weighted average common shares outstanding, basic and diluted (in shares)	1,975,610	1,906,960
Comprehensive loss:
Net loss	$ (29,769,000)	$ (29,025,000)
Other comprehensive (loss) income:
Foreign currency translation	(21,000)	(29,000)
Comprehensive loss	$ (29,790,000)	$ (29,054,000)